NEW YORK – MSF welcomes Pfizer's decision to lower the price of its pneumococcal conjugate vaccine (PCV) for children caught in humanitarian emergencies. For seven years, MSF urged Pfizer and GSK – the only two manufacturers producing the pneumonia vaccine – to offer the lowest global price to humanitarian organisations, but they refused until September, when GSK announced that it was finally reducing the price of its pneumonia vaccine for humanitarian situations.